Materials and methods
2 calculate the accumulative percentage of leakage.
18

Critical micelle concentration determination of UA-PMs
19
The critical micelle concentration (CMC) of PMs and UA-PMs in water were determined by 20 fluorescence technique using pyrene as a fluorescence probe. Specifically, 10 mL of micellar 
27
recorded from 300 to 500 nm with a scanning rate of 1200 nm/min. and the excitation 28 wavelength was 335 nm at room temperature. Meanwhile, the excitation and emission 29 bandwidth were 5 and 2.5 nm, respectively. 
55
Results
56
Stability analysis 57
We used the optimized chromatographic conditions to quantitatively determine UA. The 58 solution kept clear and showed no changes between 0 to 12 h when UA-PMs stored in 4 °C.
59
The physical stability study indicates that UA-PMs are stable with an average drug-leakage 60 rate of 2.5% during the storage within 30 days. However, the average drug-leakage rate is
61
increased to 18% at the day 60 of storage and obvious precipitates were formed at the end of 62 90-day storage with an average drug-leakage rate of 48%. Meanwhile, we also found in the 63 acceleration test, when UA-PMs were stored at the condition of 25°C ± 2°C/60% RH ± 5%
64
RH, the average drug-leakage rate is 1.5% after 5-day storage, 10% after 15-day storage.
65
After a 30-day storage, the solution became un-clear and the obvious precipitates were formed.
66
Therefore, UA-PMs should be prepared with freezing dry technology for long-term storage. 
75
CMC result of UA-PMs
76
To evaluate the stability of UA-PMs and PMs, the CMC values of them were determined 
81
Acute toxicity result of UA-PMs
82
Viscera index detection 83
The in vivo acute toxicity of UA-PMs was evaluated after a single intraperitoneal heart-toxicity to the tested mice.
99
Serum biochemical parameters 100
To further evaluate the potential toxicity of UA-PMs to the liver and kidney of mice, serum 101 biochemical indices were analyzed as shown in 
106
and Cr, no significant differences were observed between the drug experimental groups and 107 the saline control group on both day 3 and day 7 after treatment (P> 0.05). These results
108
suggested that UA-PMs had no kidney toxicity to the tested mice and only the high dose of it
109
showed side effect to the live of the tested mice.
110
Histopathological analysis 111
The histopathological study on heart, liver, spleen, lung and kidney was conducted to observe 112 whether there are pathological changes for estimating the potential toxicity of UA-PMs. As 113 described in Figure S2 , significant muscular rupture was found in the heart section of mice 
120
For both lung and kidney, the histopathological result was consistent with the detection 121 about viscera index, which indicated that UA-PMs showed no toxic effects in these two 122 8 organs.
Comparing the results about spleen toxicity to mice after treatment with UA 500 123 mg/kg, UA 750 mg/kg and UA-PMs 750 mg/kg, we found the result from viscera index was 124 not consistent with that from histopathological analysis, in which the spleen index was 125 obvious increased (Supplement table S1) but the histopathological section was normal
126
(Supplement Figure S2) . This phenomenon may because the spleen index is not sure to be 127 relative with spleen injury but it has relationship with the immune function as mentioned in 128 discussion.
129
From these results, we can see that UA-PMs at a dose of 125, 250 and 500 mg/kg
130
showed no toxic effect on normal mice and these doses may be the better choices in our
131
further experiments, but it still needs to be confirmed via the following study about antitumor 132 activities. 
133
Supplement table 1 134
161
UA-PMs (250 mg/kg) (j) UA-PMs (500 mg/kg), (k) UA-PMs (750 mg/kg).
